Following the lackluster and unconvincing results of recent trials imposed by the US FDA, the agency may restrict the marketing of Avastin (bevacizumab), the blockbuster anticancer drug made by pharmaceutical giant Roche, to exclude treatment for breast cancer.
Currently, Avastin is approved to treat metastatic colorectal cancer, non-small cell lung cancer, metastatic breast cancer, glioblastoma, and metastatic kidney cancer.
This is the second significant setback in recent weeks for Avastin. Earlier, the National Institute for Health and Clinical Excellence (NICE) in the UK rejected Avastin as a first-line treatment for metastatic breast cancer, claiming that the minimal benefits did not justify the high cost.
CANCER TYPE(S)
HER2-negative metastatic breast cancer
TREATMENT TYPE
Angiogenesis inhibitor (or anti-angiogenic agent). Avastin is a humanized monoclonal antibody that works to prevent the development of oxygen- and nutrient-delivering blood vessels to tumors.
By Ross Bonander
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
